Even though the pharmaceutical industry appears to have largely withdrawn its interest in pursuing the H3R as an anti-obesity target (189), work endures to optimize H3R ligands and explore their potential to influence food intake and body weight, and H3R antagonists/inverse agonists continue to be proposed for the treatment of obesity (190, 191). This evidence concerns the gene HRH3 and obesity disorder.